SenoRx Appoints A. Thomas Bender to Board of Directors

ALISO VIEJO, Calif., June 6, 2008 (PRIME NEWSWIRE) -- SenoRx (Nasdaq:SENO) today
announced the appointment of A. Thomas Bender to its board of directors,
effective June 5, 2008. Mr. Bender is currently Chairman of the Board of The
Cooper Companies, Inc., a position he has held since 2002. He served as
President and Chief Executive Officer of Cooper Companies from May 1994 through
his retirement in October 2007. Between 1966 and June 1991, Mr. Bender held a
variety of positions at Allergan, Inc. a manufacturer of eye and skin care
products, including Corporate Senior Vice President, and President and Chief
Operating Officer of Herbert Laboratories, Allergan's dermatology division.

"We are extremely pleased to have Tom join our board," said Lloyd Malchow,
SenoRx's president and chief executive officer. "From his time at Allergan
through his building of the Cooper Companies, Tom has repeatedly demonstrated
both his vision and commitment to shareholders. He is an excellent fit for our
Board, and I look forward to working with him.

"This board appointment is a continuation of our ongoing effort to add outside
directors with strong track records of building companies and creating
shareholder value," Malchow added.

Mr. Bender presently also serves on the Board of Directors for iScience
Interventional, Inc. and Mission Hospital Foundation, and is on the Advisory
Boards of a number of Orange County, California non-profit organizations.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical
devices used by breast care specialists for the diagnosis and treatment of
breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and
Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the
lumpectomy cavity following surgery for breast cancer. SenoRx's field sales
organization serves over 1,000 breast diagnostic and treatment centers in the
United States and Canada. In addition, SenoRx has recently launched several of
its products through distributors in more than 15 countries outside the U.S. and
Canada. The company's line of breast care products includes biopsy disposables,
biopsy capital equipment, diagnostic adjunct products and therapeutic
disposables. SenoRx is developing additional minimally invasive products for the
diagnosis and treatment of breast cancer. For more information, visit the
company's website at www.senorx.com.

The SenoRx, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3605

-0-
CONTACT: SenoRx, Inc.
Lila Churney, Director of Investor Relations
949-362-4800 x132